Heron Therapeuti Company Insiders

HRTX Stock  USD 1.69  0.07  3.98%   
Heron Therapeuti employs about 126 people. The company is managed by 16 executives with a total tenure of roughly 52 years, averaging almost 3.0 years of service per executive, having 7.88 employees per reported executive. Break down of Heron Therapeuti's management performance can provide insight into the company performance.
Sean Ristine  President
Vice President - Human Resources
Michael Mathews  President
Senior Vice President - Pain Franchise

Heron Therapeuti's Insider Buying Vs Selling

50

 
Selling
 
Buying

Latest Trades

2023-11-16William P ForbesAcquired 50000 @ 0.94View
2023-07-21Adam MorganAcquired 2486744 @ 1.37View
2022-05-03Kimberly ManhardDisposed 1504 @ 4.76View
2021-12-21Waage ChristianDisposed 300 @ 9.73View
Monitoring Heron Therapeuti's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.

Heron Therapeuti Management Team Effectiveness

The company has return on total asset (ROA) of (0.0231) % which means that it has lost $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.42 in 2024, whereas Return On Tangible Assets are likely to drop (0.52) in 2024. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 35.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.5 M in 2024.
Common Stock Shares Outstanding is likely to rise to about 145 M in 2024, whereas Net Loss is likely to drop (172 M) in 2024.

Heron Therapeuti Workforce Comparison

Heron Therapeuti is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 832. Heron Therapeuti retains roughly 126 in number of employees claiming about 15% of equities under Health Care industry.

Heron Therapeuti Profit Margins

The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.14.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.510.4875
Sufficiently Up
Slightly volatile

Heron Therapeuti Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Heron Therapeuti insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Heron Therapeuti Notable Stakeholders

A Heron Therapeuti stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Heron Therapeuti often face trade-offs trying to please all of them. Heron Therapeuti's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Heron Therapeuti's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Craig CollardCEO DirectorProfile
Sean RistineVice President - Human ResourcesProfile
Michael MathewsSenior Vice President - Pain FranchiseProfile
Thomas OttoboniSenior Vice President - Pharmaceutical and Preclinical Research and DevelopmentProfile
David SzekeresSenior Vice President General Counsel, Business Development, Corporate SecretaryProfile
Ira DuarteExecutive CFOProfile
Kimberly ManhardIndependent DirectorProfile
John PoyhonenIndependent DirectorProfile
Jeff CohnAssistant DirectorProfile
PharmD DExecutive OfficerProfile
Barry PharmDChairman CEOProfile
Lisa PerazaVP OfficerProfile
Chris StorgardChief OfficerProfile
Brett FleshmanChief OfficerProfile
Ryan CraigVice MarketingProfile
Robert SullivanSenior OperationsProfile

About Heron Therapeuti Management Performance

The success or failure of an entity such as Heron Therapeuti often depends on how effective the management is. Heron Therapeuti management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Heron management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Heron management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.50)(0.52)
Return On Capital Employed(0.77)(0.81)
Return On Assets(0.50)(0.52)
Return On Equity 3.25  3.42 
Please note, the imprecision that can be found in Heron Therapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heron Therapeuti. Check Heron Therapeuti's Beneish M Score to see the likelihood of Heron Therapeuti's management manipulating its earnings.

Heron Therapeuti Workforce Analysis

Traditionally, organizations such as Heron Therapeuti use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Heron Therapeuti within its industry.

Heron Therapeuti Manpower Efficiency

Return on Heron Therapeuti Manpower

Revenue Per Employee1M
Revenue Per Executive7.9M
Net Loss Per Employee877.5K
Net Loss Per Executive6.9M
Working Capital Per Employee865.8K
Working Capital Per Executive6.8M

Additional Tools for Heron Stock Analysis

When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.